董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Martin Edwards | 男 | Director | 64 | 未披露 | 未持股 | 2020-07-17 |
| Edward Mathers | 男 | Director | 60 | 未披露 | 未持股 | 2020-07-17 |
| Lynne Sullivan | 女 | Director | 54 | 未披露 | 未持股 | 2020-07-17 |
| Robert Hopfner | -- | Director | 48 | 未披露 | 未持股 | 2020-07-17 |
| Douglas Treco | 男 | Chairman | 62 | 未披露 | 未持股 | 2020-07-17 |
| Sarah Bhagat | 女 | Director | 34 | 未披露 | 未持股 | 2020-07-17 |
| Reinaldo Diaz | 男 | Director | 66 | 未披露 | 未持股 | 2020-07-17 |
| Robert Hopfner | -- | Director | 48 | 未披露 | 未持股 | 2020-07-17 |
| Axel Bolte | 男 | President and Chief Executive Officer, Director | 48 | 97.08万美元 | 未持股 | 2020-07-17 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Pedro Huertas | 男 | Senior Vice President, Chief Medical Officer | 66 | 未披露 | 未持股 | 2020-07-17 |
| Stephen Basso | 男 | Senior Vice President, Finance | 54 | 未披露 | 未持股 | 2020-07-17 |
| Henric Bjarke | 男 | Senior Vice President, Chief Operating Officer | 53 | 59.08万美元 | 未持股 | 2020-07-17 |
| Steven Jungles | 男 | Senior Vice President, Chief Technical Operations Officer | 55 | 48.47万美元 | 未持股 | 2020-07-17 |
| Axel Bolte | 男 | President and Chief Executive Officer, Director | 48 | 97.08万美元 | 未持股 | 2020-07-17 |
董事简历
中英对照 | 中文 | 英文- Martin Edwards
-
Martin Edwards自2015年1月起担任公司董事Dr. Edwards曾担任Novo A/S（丹麦一家有限责任公司，管理投资和金融资产）资深合伙人，他担任该职位一直到2003年10月。他是Vantia Ltd.、NeRRe Therapeutics Ltd.和Epsilon 3 Bio Ltd.董事长，这些公司都是临床分期制药公司。他还担任Tarsa Therapeutics Inc.（一家制药开发公司）、KalVista Ltd.、Karus Therapeutics Ltd.以及Acacia Pharma Ltd.董事，这些公司都是位于英国的制药公司。担任现任职位之前，Dr. Edwards从1998年到2003年担任ReNeuron Ltd.（一家总部位于英国的干细胞研究公司）首席执行官；2001年带领公司上市。他在应该曼彻斯特接受生理学与医学训练；在Warwick University接受业务训练。
Martin Edwards has served as a member of our Board since June 2019. He currently also serves on the board of directors of Verona Pharma, Reata Pharmaceuticals, Inozyme Pharma Inc. and Morphic Therapeutic. Dr. Edwards recently retired as a Senior Partner at Novo Ventures, the venture capital arm of Novo A/S from 2003 to 2020. Earlier in his career, he was Corporate VP and Global Head of Drug Development for Novo Nordisk A/S, where he led pre-clinical and clinical drug development. Previously, Dr. Edwards was Chief Executive Officer of ReNeuron Ltd. and Chief Medical Officer/Vice President at Zymogenetics. Dr. Edwards was trained in physiology and medicine at the University of Manchester, where he obtained his MBChB. He was elected a Member of the Royal College of Physicians, a Member with distinction of the Royal College of General Practitioners, a Fellow of the Faculty of Pharmaceutical Medicine and holds an MBA from the University of Warwick. In 2009 Dr. Edwards was made Adjunct Professor at CBS SIMI in Copenhagen. - Martin Edwards自2015年1月起担任公司董事Dr. Edwards曾担任Novo A/S（丹麦一家有限责任公司，管理投资和金融资产）资深合伙人，他担任该职位一直到2003年10月。他是Vantia Ltd.、NeRRe Therapeutics Ltd.和Epsilon 3 Bio Ltd.董事长，这些公司都是临床分期制药公司。他还担任Tarsa Therapeutics Inc.（一家制药开发公司）、KalVista Ltd.、Karus Therapeutics Ltd.以及Acacia Pharma Ltd.董事，这些公司都是位于英国的制药公司。担任现任职位之前，Dr. Edwards从1998年到2003年担任ReNeuron Ltd.（一家总部位于英国的干细胞研究公司）首席执行官；2001年带领公司上市。他在应该曼彻斯特接受生理学与医学训练；在Warwick University接受业务训练。
- Martin Edwards has served as a member of our Board since June 2019. He currently also serves on the board of directors of Verona Pharma, Reata Pharmaceuticals, Inozyme Pharma Inc. and Morphic Therapeutic. Dr. Edwards recently retired as a Senior Partner at Novo Ventures, the venture capital arm of Novo A/S from 2003 to 2020. Earlier in his career, he was Corporate VP and Global Head of Drug Development for Novo Nordisk A/S, where he led pre-clinical and clinical drug development. Previously, Dr. Edwards was Chief Executive Officer of ReNeuron Ltd. and Chief Medical Officer/Vice President at Zymogenetics. Dr. Edwards was trained in physiology and medicine at the University of Manchester, where he obtained his MBChB. He was elected a Member of the Royal College of Physicians, a Member with distinction of the Royal College of General Practitioners, a Fellow of the Faculty of Pharmaceutical Medicine and holds an MBA from the University of Warwick. In 2009 Dr. Edwards was made Adjunct Professor at CBS SIMI in Copenhagen.
- Edward Mathers
-
Edward Mathers，自Senti Biosciences，Inc.业务合并于2022年6月结束以来一直担任Senti Biosciences，Inc.董事会成员，在Senti Biosciences，Inc.业务合并之前，自2016年7月起担任Legacy Senti董事会成员。Mathers先生自2019年11月起担任New Enterprise Associates，Inc.（NEA）的普通合伙人，该公司是一家专注于技术和医疗保健投资的私营风险投资公司，在此之前，于2008年8月至2019年10月担任NEA的合伙人。在加入NEA之前，Mathers先生曾在生物制药公司MedImmune，Inc.担任企业发展和风险投资执行副总裁，并于2008年6月至2022年6月期间领导其风险投资子公司MedImmune Ventures，Inc.。Mathers先生目前担任Affinia Therapeutics，Code Biotherapeutics，Inc.，Inozyme Pharma, Inc.（NASDAQ：INZY），Inversago Pharma，MBX Biosciences，Inc.，ObsEva SA（NASDAQ：OBSV），Reneo Pharmaceuticals, Inc.（NASDAQ：RPHM），TERM4（NASDAQ：TERM5），Rhythm Pharmaceuticals, Inc.TERM6（NASDAQ：RYTM），Shape Therapeutics Inc.，Sorriso Pharmaceuticals，Inc.，SpliceBio，SL，Synlogic, Inc.TERM8（NASDAQ：SYBX）原名自2017年10月至2022年12月被上市生物制药公司礼来 and Company（NYSE：LLY）、Mirum Pharmaceuticals, Inc.，Inc.（NASDAQ：MIRM）收购，自2018年11月至2022年9月，上市生物制药公司Lumos Pharma, Inc.，TERM4，Inc.（NASDAQ：LUMO）于2014年1月至2020年3月与NewLink Genetics Corporation（NASDAQ：NLINK）、Liquidia Technologies, Inc.TERM6（NASDAQ：LQDA）合并，上市生物制药公司TERM6，Inc.（NASDAQ：TERM7）于2009年4月至2019年5月被上市生物制药公司收购，而Ra Pharmaceuticals, Inc.，Inc.（NASDAQ：RARX）于2010年2月至2020年4月被UCIC收购马瑟斯先生在北卡罗来纳州立大学获得化学学士学位。
Edward Mathers has served as a member of Synlogic, Inc. Board since October 2012. Mr. Mathers previoly served on the Private Synlogic board of directors since July 2014. Mr. Mathers is a General Partner at NEA, a private venture capital firm focing on technology and healthcare investments. Mr. Mathers serves on the board of directors of the following publicly traded pharmaceutical companies: Trevi Therapeutics, Inc., Rhythm Pharmaceuticals, Inc., OnKure Therapeutics, Inc., formerly known as Reneo Pharmaceuticals, Inc., MBX Biosciences, Inc. and Senti Biosciences, Inc. Mr. Mathers also serves on the board of directors of several privately held companies. Mr. Mathers previoly served on the board of directors of the following publicly traded companies: ObsEva SA, Mirum Pharmaceuticals, Inc., Akouos, Inc., Lumos Pharma, Inc., and Ra Pharmaceuticals, Inc. From 2002 to 2008, Mr. Mathers served as Executive Vice President, Corporate Development and Venture at MedImmune, Inc., a biopharmaceutical company, and led its venture capital subsidiary, MedImmune Ventures, Inc. Before joining MedImmune in 2002, Mr. Mathers was Vice President, Marketing and Corporate Licensing and Acquisitions at Inhale Therapeutic Systems, a biotechnology company. Previoly, Mr. Mathers spent 15 years at Glaxo llcome, Inc. (GlaxoSmithKline), a pharmaceutical company, where he held vario sales and marketing positions. Mr. Mathers received a B.S. in Chemistry from North Carolina State University. - Edward Mathers，自Senti Biosciences，Inc.业务合并于2022年6月结束以来一直担任Senti Biosciences，Inc.董事会成员，在Senti Biosciences，Inc.业务合并之前，自2016年7月起担任Legacy Senti董事会成员。Mathers先生自2019年11月起担任New Enterprise Associates，Inc.（NEA）的普通合伙人，该公司是一家专注于技术和医疗保健投资的私营风险投资公司，在此之前，于2008年8月至2019年10月担任NEA的合伙人。在加入NEA之前，Mathers先生曾在生物制药公司MedImmune，Inc.担任企业发展和风险投资执行副总裁，并于2008年6月至2022年6月期间领导其风险投资子公司MedImmune Ventures，Inc.。Mathers先生目前担任Affinia Therapeutics，Code Biotherapeutics，Inc.，Inozyme Pharma, Inc.（NASDAQ：INZY），Inversago Pharma，MBX Biosciences，Inc.，ObsEva SA（NASDAQ：OBSV），Reneo Pharmaceuticals, Inc.（NASDAQ：RPHM），TERM4（NASDAQ：TERM5），Rhythm Pharmaceuticals, Inc.TERM6（NASDAQ：RYTM），Shape Therapeutics Inc.，Sorriso Pharmaceuticals，Inc.，SpliceBio，SL，Synlogic, Inc.TERM8（NASDAQ：SYBX）原名自2017年10月至2022年12月被上市生物制药公司礼来 and Company（NYSE：LLY）、Mirum Pharmaceuticals, Inc.，Inc.（NASDAQ：MIRM）收购，自2018年11月至2022年9月，上市生物制药公司Lumos Pharma, Inc.，TERM4，Inc.（NASDAQ：LUMO）于2014年1月至2020年3月与NewLink Genetics Corporation（NASDAQ：NLINK）、Liquidia Technologies, Inc.TERM6（NASDAQ：LQDA）合并，上市生物制药公司TERM6，Inc.（NASDAQ：TERM7）于2009年4月至2019年5月被上市生物制药公司收购，而Ra Pharmaceuticals, Inc.，Inc.（NASDAQ：RARX）于2010年2月至2020年4月被UCIC收购马瑟斯先生在北卡罗来纳州立大学获得化学学士学位。
- Edward Mathers has served as a member of Synlogic, Inc. Board since October 2012. Mr. Mathers previoly served on the Private Synlogic board of directors since July 2014. Mr. Mathers is a General Partner at NEA, a private venture capital firm focing on technology and healthcare investments. Mr. Mathers serves on the board of directors of the following publicly traded pharmaceutical companies: Trevi Therapeutics, Inc., Rhythm Pharmaceuticals, Inc., OnKure Therapeutics, Inc., formerly known as Reneo Pharmaceuticals, Inc., MBX Biosciences, Inc. and Senti Biosciences, Inc. Mr. Mathers also serves on the board of directors of several privately held companies. Mr. Mathers previoly served on the board of directors of the following publicly traded companies: ObsEva SA, Mirum Pharmaceuticals, Inc., Akouos, Inc., Lumos Pharma, Inc., and Ra Pharmaceuticals, Inc. From 2002 to 2008, Mr. Mathers served as Executive Vice President, Corporate Development and Venture at MedImmune, Inc., a biopharmaceutical company, and led its venture capital subsidiary, MedImmune Ventures, Inc. Before joining MedImmune in 2002, Mr. Mathers was Vice President, Marketing and Corporate Licensing and Acquisitions at Inhale Therapeutic Systems, a biotechnology company. Previoly, Mr. Mathers spent 15 years at Glaxo llcome, Inc. (GlaxoSmithKline), a pharmaceutical company, where he held vario sales and marketing positions. Mr. Mathers received a B.S. in Chemistry from North Carolina State University.
- Lynne Sullivan
-
Lynne Sullivan自2017年12月以来一直担任我们的董事会成员。Sullivan女士于2019年8月从Compass Therapeutics，LLC退休，自2018年12月起担任首席财务官。此前，沙利文女士最近于2016年9月至2018年12月担任BiogenInc.财务高级副总裁。在此之前，Sullivan女士于2015年6月至2018年12月担任高级副总裁，税务和公司财务主管。2008年4月至2015年6月，沙利文女士还担任税务Vice President。在BiogenInc.，沙利文女士负责Biogen&；8217；S的财务规划与分析、公司税和公司融资集团，其中包括长期规划、资本配置项目的所有权以及并购/业务发展的财务方面。2000年1月至2008年4月，Sullivan女士担任EMD Serono的Vice President税务和Merck KGaA的北美税务Vice President。Sullivan女士是Biomx Inc.和Solid Biosciences LLC的董事会成员，自2015年起担任审计委员会主席。Sullivan女士拥有萨福克大学（Suffolk University）会计学士学位和本特利学院（Bentley College）税务硕士学位。Sullivan女士担任了20多年的注册会计师。
Lynne Sullivan has served as Chief Financial Officer since July 2020 and Head of Corporate Development since January 29 2021. Previously, Ms. Sullivan was Chief Financial Officer at Compass Therapeutics, LLC from December 2018 to August 2019. Prior to that, Ms. Sullivan most recently served as Senior Vice President of Finance for Biogen Inc. NASDAQ: BIIB from September 2016 to December 2018. Prior to joining Biogen, Ms. Sullivan served as Senior Vice President, Tax and Corporate Finance for Biogen from June 2015 to December 2018 and served as Vice President, Tax for Biogen from April 2008 to June 2015. From January 2000 through April 2008 Ms. Sullivan served as Vice President Tax for EMD Serono and the Vice President of Tax for North America at Merck KgaA. Ms. Sullivan also currently serves as a member of the boards of directors and as chair of the audit committees of a number of public biopharmaceutical companies, including Solid Biosciences Inc., Inozyme Pharma, and BiomX Inc. Ms. Sullivan holds an M.S. in taxation from Bentley University and a B.S.B.A. from Suffolk University. - Lynne Sullivan自2017年12月以来一直担任我们的董事会成员。Sullivan女士于2019年8月从Compass Therapeutics，LLC退休，自2018年12月起担任首席财务官。此前，沙利文女士最近于2016年9月至2018年12月担任BiogenInc.财务高级副总裁。在此之前，Sullivan女士于2015年6月至2018年12月担任高级副总裁，税务和公司财务主管。2008年4月至2015年6月，沙利文女士还担任税务Vice President。在BiogenInc.，沙利文女士负责Biogen&；8217；S的财务规划与分析、公司税和公司融资集团，其中包括长期规划、资本配置项目的所有权以及并购/业务发展的财务方面。2000年1月至2008年4月，Sullivan女士担任EMD Serono的Vice President税务和Merck KGaA的北美税务Vice President。Sullivan女士是Biomx Inc.和Solid Biosciences LLC的董事会成员，自2015年起担任审计委员会主席。Sullivan女士拥有萨福克大学（Suffolk University）会计学士学位和本特利学院（Bentley College）税务硕士学位。Sullivan女士担任了20多年的注册会计师。
- Lynne Sullivan has served as Chief Financial Officer since July 2020 and Head of Corporate Development since January 29 2021. Previously, Ms. Sullivan was Chief Financial Officer at Compass Therapeutics, LLC from December 2018 to August 2019. Prior to that, Ms. Sullivan most recently served as Senior Vice President of Finance for Biogen Inc. NASDAQ: BIIB from September 2016 to December 2018. Prior to joining Biogen, Ms. Sullivan served as Senior Vice President, Tax and Corporate Finance for Biogen from June 2015 to December 2018 and served as Vice President, Tax for Biogen from April 2008 to June 2015. From January 2000 through April 2008 Ms. Sullivan served as Vice President Tax for EMD Serono and the Vice President of Tax for North America at Merck KgaA. Ms. Sullivan also currently serves as a member of the boards of directors and as chair of the audit committees of a number of public biopharmaceutical companies, including Solid Biosciences Inc., Inozyme Pharma, and BiomX Inc. Ms. Sullivan holds an M.S. in taxation from Bentley University and a B.S.B.A. from Suffolk University.
- Robert Hopfner
-
Robert Hopfner于2017年12月至2018年5月24日担任董事会成员。自2017年10月以来，Hopfner博士一直担任风险投资公司Pivotal BioVenture Partners LLC的管理合伙人。2007年至2017年9月，Hopfner博士担任风险投资公司Bay City Capital的投资合伙人。加入Bay City Capital之前，Hopfner曾担任DuPont Pharmaceuticals’；Business Development&Strategic Planning Group合伙人，以及AG-West Biotech（加拿大西部种子阶段生物技术风险投资公司）分析师。Hopfner博士曾在Durata公司和HyperionTherapeutics，Inc.公司的董事会任职。Hopfner博士拥有萨斯喀彻温大学（University of Saskatchewan）的药理学博士学位和药学学士学位，以及芝加哥大学布斯商学院（University of Chicago Booth School of Business）的工商管理硕士学位，专攻创业、金融和战略。
Robert Hopfner served as a member of our board of directors from December 2017 to May 24 2018. Since October 2017 Dr. Hopfner has served as a managing partner at Pivotal bioVenture Partners LLC, a venture capital firm. From 2007 to September 2017 Dr. Hopfner served as an investment partner at Bay City Capital, a venture capital firm. Before joining Bay City Capital, Dr. Hopfner worked as an associate in DuPont Pharmaceuticals’ business development & strategic planning group and as an analyst at Ag-West Biotech, a Western Canadian seed-stage biotech venture capital firm. Dr. Hopfner previously served on the boards of directors of Durata and Hyperion Therapeutics, Inc. Dr. Hopfner holds Ph.D. in pharmacology and a B.S. in pharmacy from the University of Saskatchewan and an M.B.A. with specializations in entrepreneurship, finance and strategy from the University of Chicago Booth School of Business. - Robert Hopfner于2017年12月至2018年5月24日担任董事会成员。自2017年10月以来，Hopfner博士一直担任风险投资公司Pivotal BioVenture Partners LLC的管理合伙人。2007年至2017年9月，Hopfner博士担任风险投资公司Bay City Capital的投资合伙人。加入Bay City Capital之前，Hopfner曾担任DuPont Pharmaceuticals’；Business Development&Strategic Planning Group合伙人，以及AG-West Biotech（加拿大西部种子阶段生物技术风险投资公司）分析师。Hopfner博士曾在Durata公司和HyperionTherapeutics，Inc.公司的董事会任职。Hopfner博士拥有萨斯喀彻温大学（University of Saskatchewan）的药理学博士学位和药学学士学位，以及芝加哥大学布斯商学院（University of Chicago Booth School of Business）的工商管理硕士学位，专攻创业、金融和战略。
- Robert Hopfner served as a member of our board of directors from December 2017 to May 24 2018. Since October 2017 Dr. Hopfner has served as a managing partner at Pivotal bioVenture Partners LLC, a venture capital firm. From 2007 to September 2017 Dr. Hopfner served as an investment partner at Bay City Capital, a venture capital firm. Before joining Bay City Capital, Dr. Hopfner worked as an associate in DuPont Pharmaceuticals’ business development & strategic planning group and as an analyst at Ag-West Biotech, a Western Canadian seed-stage biotech venture capital firm. Dr. Hopfner previously served on the boards of directors of Durata and Hyperion Therapeutics, Inc. Dr. Hopfner holds Ph.D. in pharmacology and a B.S. in pharmacy from the University of Saskatchewan and an M.B.A. with specializations in entrepreneurship, finance and strategy from the University of Chicago Booth School of Business.
- Douglas Treco
-
Douglas Treco自2020年5月以来一直担任我们的董事会主席。Treco博士于2008年共同创立了RaPharmaceuticals，Inc.（Ra Pharma），这是一家制药公司，于2020年4月被UCB S.A.收购。他自2008年6月起担任RA Pharma的总裁兼首席执行官。Treco从2008年1月到2014年5月担任Morgenthaler Ventures（一家风险投资公司）常驻企业家。Treco博士从2004年到2007年担任马萨诸塞州总医院（Massachusetts General Hospital）分子生物系客座科学家以及哈佛医学院（Harvard Medical School）遗传学讲师。Treco博士目前担任CRISPR Therapeutics AG董事会成员，并于2008年6月至2020年4月担任RA Pharma董事会成员。Treco博士在特拉华大学（University of Delaware）获得生物学学士学位，在纽约州立大学石溪分校（State University of New York，Stony Brook）获得生物化学与分子生物学博士学位，并在索尔克生物研究所（Salk Institute for Biological Studies）和马萨诸塞州总医院（Massachusetts General Hospital）进行博士后研究。
Douglas Treco has served as the chairman of our board of directors since May 2020. Dr. Treco co-founded RA Pharmaceuticals, Inc., or RA Pharma, a pharmaceutical company, in 2008 which was acquired by UCB S.A. in April 2020. He has served as the president and chief executive officer of Ra Pharma since June 2008. Dr. Treco served as an entrepreneur-in-residence with Morgenthaler Ventures, a venture capital firm, from January 2008 to May 2014. Dr. Treco served as a visiting scientist in the Department of Molecular Biology at Massachusetts General Hospital and as a lecturer in genetics at Harvard Medical School from 2004 to 2007. Dr. Treco currently serves on the board of directors of CRISPR Therapeutics AG and served on the board of directors of Ra Pharma from June 2008 to April 2020. Dr. Treco received a B.A. in Biology from the University of Delaware and a Ph.D. in biochemistry and molecular biology from the State University of New York, Stony Brook, and performed post-doctoral research at the Salk Institute for Biological Studies and Massachusetts General Hospital. - Douglas Treco自2020年5月以来一直担任我们的董事会主席。Treco博士于2008年共同创立了RaPharmaceuticals，Inc.（Ra Pharma），这是一家制药公司，于2020年4月被UCB S.A.收购。他自2008年6月起担任RA Pharma的总裁兼首席执行官。Treco从2008年1月到2014年5月担任Morgenthaler Ventures（一家风险投资公司）常驻企业家。Treco博士从2004年到2007年担任马萨诸塞州总医院（Massachusetts General Hospital）分子生物系客座科学家以及哈佛医学院（Harvard Medical School）遗传学讲师。Treco博士目前担任CRISPR Therapeutics AG董事会成员，并于2008年6月至2020年4月担任RA Pharma董事会成员。Treco博士在特拉华大学（University of Delaware）获得生物学学士学位，在纽约州立大学石溪分校（State University of New York，Stony Brook）获得生物化学与分子生物学博士学位，并在索尔克生物研究所（Salk Institute for Biological Studies）和马萨诸塞州总医院（Massachusetts General Hospital）进行博士后研究。
- Douglas Treco has served as the chairman of our board of directors since May 2020. Dr. Treco co-founded RA Pharmaceuticals, Inc., or RA Pharma, a pharmaceutical company, in 2008 which was acquired by UCB S.A. in April 2020. He has served as the president and chief executive officer of Ra Pharma since June 2008. Dr. Treco served as an entrepreneur-in-residence with Morgenthaler Ventures, a venture capital firm, from January 2008 to May 2014. Dr. Treco served as a visiting scientist in the Department of Molecular Biology at Massachusetts General Hospital and as a lecturer in genetics at Harvard Medical School from 2004 to 2007. Dr. Treco currently serves on the board of directors of CRISPR Therapeutics AG and served on the board of directors of Ra Pharma from June 2008 to April 2020. Dr. Treco received a B.A. in Biology from the University of Delaware and a Ph.D. in biochemistry and molecular biology from the State University of New York, Stony Brook, and performed post-doctoral research at the Salk Institute for Biological Studies and Massachusetts General Hospital.
- Sarah Bhagat
-
Sarah Bhagat自2019年3月以来一直担任我们的董事会成员。Bhagat博士自2020年3月起担任风险投资公司Sofinnova Investments，Inc.或Sofinnova的合伙人。她于2019年1月至2019年12月担任Sofinnova的负责人，并于2017年5月至2018年12月担任合伙人。Bhagat博士于2016年4月至2017年5月担任斯坦福大学博士后。Bhagat博士于2015年2月至2016年2月担任风险投资公司Canaan Partners的风险研究员。Bhagat博士还从2008年5月到2010年5月担任洛克菲勒大学（Rockefeller University）的研究助理，从2007年6月到2008年5月担任马萨诸塞州总医院（Massachusetts General Hospital）的临床研究协调员。Bhagat博士在富兰克林&马歇尔学院（Franklin&Marshall College）获得生物心理学学士学位，并在耶鲁大学（Yale University）获得神经科学博士学位。
Sarah Bhagat has served on our board of directors since March 2019. Dr. Bhagat has served as a partner at Sofinnova Investments, Inc., or Sofinnova, a venture capital firm, since March 2020. She served as principal at Sofinnova from January 2019 to December 2019 and as an associate from May 2017 to December 2018. Dr. Bhagat was a postdoctoral fellow at Stanford University from April 2016 to May 2017. Dr. Bhagat served as a venture fellow at Canaan Partners, a venture capital firm, from February 2015 to February 2016. Dr. Bhagat also served as a research assistant at The Rockefeller University from May 2008 to May 2010 and a clinical research coordinator at Massachusetts General Hospital from June 2007 to May 2008. Dr. Bhagat received a B.A. in biological psychology from Franklin & Marshall College and a Ph.D. in neuroscience from Yale University. - Sarah Bhagat自2019年3月以来一直担任我们的董事会成员。Bhagat博士自2020年3月起担任风险投资公司Sofinnova Investments，Inc.或Sofinnova的合伙人。她于2019年1月至2019年12月担任Sofinnova的负责人，并于2017年5月至2018年12月担任合伙人。Bhagat博士于2016年4月至2017年5月担任斯坦福大学博士后。Bhagat博士于2015年2月至2016年2月担任风险投资公司Canaan Partners的风险研究员。Bhagat博士还从2008年5月到2010年5月担任洛克菲勒大学（Rockefeller University）的研究助理，从2007年6月到2008年5月担任马萨诸塞州总医院（Massachusetts General Hospital）的临床研究协调员。Bhagat博士在富兰克林&马歇尔学院（Franklin&Marshall College）获得生物心理学学士学位，并在耶鲁大学（Yale University）获得神经科学博士学位。
- Sarah Bhagat has served on our board of directors since March 2019. Dr. Bhagat has served as a partner at Sofinnova Investments, Inc., or Sofinnova, a venture capital firm, since March 2020. She served as principal at Sofinnova from January 2019 to December 2019 and as an associate from May 2017 to December 2018. Dr. Bhagat was a postdoctoral fellow at Stanford University from April 2016 to May 2017. Dr. Bhagat served as a venture fellow at Canaan Partners, a venture capital firm, from February 2015 to February 2016. Dr. Bhagat also served as a research assistant at The Rockefeller University from May 2008 to May 2010 and a clinical research coordinator at Massachusetts General Hospital from June 2007 to May 2008. Dr. Bhagat received a B.A. in biological psychology from Franklin & Marshall College and a Ph.D. in neuroscience from Yale University.
- Reinaldo Diaz
-
Reinaldo Diaz自2017年1月以来一直担任我们的董事会成员。Diaz先生自2015年11月起担任专注于梦百合公司的风险投资公司Longitude Capital Management Co.，LLC的风险合伙人。Diaz自2005年起担任DA Advisors，LLC（一家专注于生物制药公司的金融和战略咨询公司）管理成员和董事总经理。Diaz先生于2008年至2018年担任私募股权公司Auven Therapeutics的董事总经理，该公司专注于生命科学。Diaz从1996年到2005年担任Diaz&Altschul Capital Management，LLC（一家专注于梦百合公司的资产管理公司）管理成员和联合创始人。Diaz先生从1993年到1996年担任Schroder Wertheim&Co.，Inc.的常务董事兼梦百合集团负责人。Diaz从1985年到1993年在PaineWebber Development Corporation担任多个职位，包括从1990年到1993年担任总裁。Diaz先生在哈佛大学（Harvard University）获得通识研究学士学位，并在哈佛商学院（Harvard Business School）获得工商管理硕士学位。
Reinaldo Diaz,has served as a member of Lexeo Therapeutics, Inc. board of directors since February 2022. Mr. Diaz has served as a Venture Partner at Longitude Capital, a healthcare venture capital firm since 2015, and he currently serves as the Chief Business Officer of Opna-Immuno Oncology, SA, a Longitude Capital portfolio company. Mr. Diaz has also served as a Managing Director of DA Advisors, LLC since 2005, providing strategic and financial advice primarily to life science companies. From 2008 to 2018, Mr. Diaz served as a managing director at Auven Therapeutics, a private equity firm focusing on life science companies. From 1996 to 2005, Mr. Diaz served as a managing member and co-founder of Diaz & Altschul Capital Management, LLC, an asset management firm focusing on healthcare companies. Prior to that, Mr. Diaz served as a managing director and head of the healthcare group at Schroder Wertheim & Co., Inc., and in various roles at PaineWebber Development Corporation, including as president. Mr. Diaz currently serves on the board of directors of the public pharmaceutical company, Inozyme Pharma, Inc. Mr. Diaz received a B.A. in General Studies from Harvard University and an M.B.A. from Harvard Business School. - Reinaldo Diaz自2017年1月以来一直担任我们的董事会成员。Diaz先生自2015年11月起担任专注于梦百合公司的风险投资公司Longitude Capital Management Co.，LLC的风险合伙人。Diaz自2005年起担任DA Advisors，LLC（一家专注于生物制药公司的金融和战略咨询公司）管理成员和董事总经理。Diaz先生于2008年至2018年担任私募股权公司Auven Therapeutics的董事总经理，该公司专注于生命科学。Diaz从1996年到2005年担任Diaz&Altschul Capital Management，LLC（一家专注于梦百合公司的资产管理公司）管理成员和联合创始人。Diaz先生从1993年到1996年担任Schroder Wertheim&Co.，Inc.的常务董事兼梦百合集团负责人。Diaz从1985年到1993年在PaineWebber Development Corporation担任多个职位，包括从1990年到1993年担任总裁。Diaz先生在哈佛大学（Harvard University）获得通识研究学士学位，并在哈佛商学院（Harvard Business School）获得工商管理硕士学位。
- Reinaldo Diaz,has served as a member of Lexeo Therapeutics, Inc. board of directors since February 2022. Mr. Diaz has served as a Venture Partner at Longitude Capital, a healthcare venture capital firm since 2015, and he currently serves as the Chief Business Officer of Opna-Immuno Oncology, SA, a Longitude Capital portfolio company. Mr. Diaz has also served as a Managing Director of DA Advisors, LLC since 2005, providing strategic and financial advice primarily to life science companies. From 2008 to 2018, Mr. Diaz served as a managing director at Auven Therapeutics, a private equity firm focusing on life science companies. From 1996 to 2005, Mr. Diaz served as a managing member and co-founder of Diaz & Altschul Capital Management, LLC, an asset management firm focusing on healthcare companies. Prior to that, Mr. Diaz served as a managing director and head of the healthcare group at Schroder Wertheim & Co., Inc., and in various roles at PaineWebber Development Corporation, including as president. Mr. Diaz currently serves on the board of directors of the public pharmaceutical company, Inozyme Pharma, Inc. Mr. Diaz received a B.A. in General Studies from Harvard University and an M.B.A. from Harvard Business School.
- Robert Hopfner
-
暂无中文简介
Robert Hopfner has served on our board of directors since November 2018. Dr. Hopfner has served as managing partner of Pivotal bioVenture Partners, a venture capital firm focused on life sciences, since October 2017. Dr. Hopfner served in various roles at Bay City Capital, a venture capital firm focused on life sciences, from August 2002 to October 2017 including as a principal from June 2007 to October 2009 and as managing director and investment partner from October 2009 to October 2017. Dr. Hopfner currently serves on the board of directors of Vaxcyte, Inc., a publicly traded vaccine company. Dr. Hopfner received a B.S. in pharmacy from the University of Saskatchewan, an M.B.A. from the University of Chicago Booth School of Business and a Ph.D. in pharmacology from the University of Saskatchewan. -
暂无中文简介
- Robert Hopfner has served on our board of directors since November 2018. Dr. Hopfner has served as managing partner of Pivotal bioVenture Partners, a venture capital firm focused on life sciences, since October 2017. Dr. Hopfner served in various roles at Bay City Capital, a venture capital firm focused on life sciences, from August 2002 to October 2017 including as a principal from June 2007 to October 2009 and as managing director and investment partner from October 2009 to October 2017. Dr. Hopfner currently serves on the board of directors of Vaxcyte, Inc., a publicly traded vaccine company. Dr. Hopfner received a B.S. in pharmacy from the University of Saskatchewan, an M.B.A. from the University of Chicago Booth School of Business and a Ph.D. in pharmacology from the University of Saskatchewan.
- Axel Bolte
-
Axel Bolte，2003年12月起，担任本公司董事。2003年3月起，他担任HBM Partners AG的投资顾问，这是生命科学行业的投资咨询服务提供商。2001年3月至2003年2月，他是NMT New Medical Technologies AG的投资经理，这是专注于生命科学行业的瑞士风投公司。加入NMT New Medical Technologies AG之前，他是生物技术公司Serono SA的科学家。他目前担任一些生物技术公司的董事，其中包括：Newron Pharmaceuticals SpA、Nabriva Therapeutics AG、Opthotech Corporation、MPex Pharmaceuticals, Inc.、Lux Biosciences, Inc.和 Kolltan Pharmaceuticals, Inc.。他获得了瑞士University of St. Gallen的工商管理硕士学士学位、瑞士苏黎世Swiss Federal Institute of Technology的生物化学学位。
Axel Bolte has served as a member of our board of directors since August 2007. From March 2003 through January 2017 Mr. Bolte served as investment advisor to HBM Partners AG, a provider of investment advisory services in the life sciences industry. From February 2017 to September 2019 Mr. Bolte served as a venture partner to HBM Partners AG. In February 2017 Mr. Bolte began serving as president and chief executive officer of Inozyme Pharma Inc., a private biotechnology company, and as a managing member of Healthcare Advisors GmbH, a private healthcare advisory company. Mr. Bolte previously served on the boards of directors of Allena Pharmaceuticals, Inc. and Nabriva Therapeutics AG, both of which are publicly traded biotechnology or pharmaceutical companies. Mr. Bolte received a degree in biochemistry from the Swiss Federal Institute of Technology, Zurich, Switzerland and an M.B.A. from the University of St. Gallen, Switzerland. - Axel Bolte，2003年12月起，担任本公司董事。2003年3月起，他担任HBM Partners AG的投资顾问，这是生命科学行业的投资咨询服务提供商。2001年3月至2003年2月，他是NMT New Medical Technologies AG的投资经理，这是专注于生命科学行业的瑞士风投公司。加入NMT New Medical Technologies AG之前，他是生物技术公司Serono SA的科学家。他目前担任一些生物技术公司的董事，其中包括：Newron Pharmaceuticals SpA、Nabriva Therapeutics AG、Opthotech Corporation、MPex Pharmaceuticals, Inc.、Lux Biosciences, Inc.和 Kolltan Pharmaceuticals, Inc.。他获得了瑞士University of St. Gallen的工商管理硕士学士学位、瑞士苏黎世Swiss Federal Institute of Technology的生物化学学位。
- Axel Bolte has served as a member of our board of directors since August 2007. From March 2003 through January 2017 Mr. Bolte served as investment advisor to HBM Partners AG, a provider of investment advisory services in the life sciences industry. From February 2017 to September 2019 Mr. Bolte served as a venture partner to HBM Partners AG. In February 2017 Mr. Bolte began serving as president and chief executive officer of Inozyme Pharma Inc., a private biotechnology company, and as a managing member of Healthcare Advisors GmbH, a private healthcare advisory company. Mr. Bolte previously served on the boards of directors of Allena Pharmaceuticals, Inc. and Nabriva Therapeutics AG, both of which are publicly traded biotechnology or pharmaceutical companies. Mr. Bolte received a degree in biochemistry from the Swiss Federal Institute of Technology, Zurich, Switzerland and an M.B.A. from the University of St. Gallen, Switzerland.
高管简历
中英对照 | 中文 | 英文- Pedro Huertas
Pedro Huertas自2017年12月起担任首席医疗官，此前自2015年5月起担任Private Eloxx的首席医疗官。在此之前，Huertas从2012年到2015年5月在Precision Medicine担任Pfizer Worldwide Research&Development临床负责人和罕见病精准医疗主管。他也曾担任Genzyme公司、Shire公司和Amicus Therapeutics公司的高级职务。Huertas博士毕业于斯坦福大学生物化学硕士学位，哈佛大学细胞与发育生物学博士学位，哈佛医学院与麻省理工学院医学博士之间的健康科学与技术课程，以及麻省理工学院斯隆管理学院管理硕士学位。他在马萨诸塞州总医院（Massachusetts General Hospital）接受内科、风湿病和姑息治疗方面的培训。
Pedro Huertas has served as our Chief Medical Officer since December 2017 and was previously the Chief Medical Officer of Private Eloxx beginning in May 2015. Prior to that, Dr. Huertas’ was with Precision Medicine as Clinical Lead and Head of Precision Medicine for Rare Diseases at Pfizer Worldwide Research & Development from 2012 until May 2015. He also previously held senior roles and Genzyme, Shire and Amicus Therapeutics. Dr. Huertas is a graduate of Stanford University MS, Biochemistry, Harvard University PhD, Cell and Developmental Biology, the Program in Health Sciences and Technology between Harvard Medical School and the Massachusetts Institute of Technology MD, and the Sloan School of Management at the Massachusetts Institute of Technology MS, Management. He trained in Internal Medicine, Rheumatology, and Palliative Care at Massachusetts General Hospital.- Pedro Huertas自2017年12月起担任首席医疗官，此前自2015年5月起担任Private Eloxx的首席医疗官。在此之前，Huertas从2012年到2015年5月在Precision Medicine担任Pfizer Worldwide Research&Development临床负责人和罕见病精准医疗主管。他也曾担任Genzyme公司、Shire公司和Amicus Therapeutics公司的高级职务。Huertas博士毕业于斯坦福大学生物化学硕士学位，哈佛大学细胞与发育生物学博士学位，哈佛医学院与麻省理工学院医学博士之间的健康科学与技术课程，以及麻省理工学院斯隆管理学院管理硕士学位。他在马萨诸塞州总医院（Massachusetts General Hospital）接受内科、风湿病和姑息治疗方面的培训。
- Pedro Huertas has served as our Chief Medical Officer since December 2017 and was previously the Chief Medical Officer of Private Eloxx beginning in May 2015. Prior to that, Dr. Huertas’ was with Precision Medicine as Clinical Lead and Head of Precision Medicine for Rare Diseases at Pfizer Worldwide Research & Development from 2012 until May 2015. He also previously held senior roles and Genzyme, Shire and Amicus Therapeutics. Dr. Huertas is a graduate of Stanford University MS, Biochemistry, Harvard University PhD, Cell and Developmental Biology, the Program in Health Sciences and Technology between Harvard Medical School and the Massachusetts Institute of Technology MD, and the Sloan School of Management at the Massachusetts Institute of Technology MS, Management. He trained in Internal Medicine, Rheumatology, and Palliative Care at Massachusetts General Hospital.
- Stephen Basso
Stephen Basso自2020年1月起担任我们的高级副总裁，财务。Basso先生于2017年10月至2020年1月担任我们的财务Vice President。在加入我们公司之前，巴索曾于2016年5月至2017年5月Vice President亚力兄制药公司或Alexion担任多个职位，其中包括Vice President、北美商业和全球一般和行政金融公司，2014年2月至2016年5月担任公司财务规划和分析执行董事，2011年7月至2014年2月担任财务执行董事，2009年1月至2011年7月担任财务和规划高级董事。在加入Alexion之前，巴索曾在制药公司辉瑞公司（Pfizer）担任多个财务职位。Basso先生在普罗维登斯学院（Providence College）获得商业学士学位，并在波士顿学院（Boston College）获得工商管理硕士学位。
Stephen Basso has served as our senior vice president, finance since January 2020. Mr. Basso served as our vice president, finance from October 2017 to January 2020. Prior to joining our company, Mr. Basso held a variety of positions at Alexion Pharmaceuticals, Inc., or Alexion, a pharmaceutical company, including vice president, North America commercial and global general and administrative finance from May 2016 to May 2017 vice president, corporate financial planning and analysis from February 2014 to May 2016 executive director, finance from July 2011 to February 2014 and senior director, finance and planning from January 2009 to July 2011. Prior to joining Alexion, Mr. Basso served in various finance roles at Pfizer Inc., or Pfizer, a pharmaceutical company. Mr. Basso received a B.S. in business from Providence College and an M.B.A. from Boston College.- Stephen Basso自2020年1月起担任我们的高级副总裁，财务。Basso先生于2017年10月至2020年1月担任我们的财务Vice President。在加入我们公司之前，巴索曾于2016年5月至2017年5月Vice President亚力兄制药公司或Alexion担任多个职位，其中包括Vice President、北美商业和全球一般和行政金融公司，2014年2月至2016年5月担任公司财务规划和分析执行董事，2011年7月至2014年2月担任财务执行董事，2009年1月至2011年7月担任财务和规划高级董事。在加入Alexion之前，巴索曾在制药公司辉瑞公司（Pfizer）担任多个财务职位。Basso先生在普罗维登斯学院（Providence College）获得商业学士学位，并在波士顿学院（Boston College）获得工商管理硕士学位。
- Stephen Basso has served as our senior vice president, finance since January 2020. Mr. Basso served as our vice president, finance from October 2017 to January 2020. Prior to joining our company, Mr. Basso held a variety of positions at Alexion Pharmaceuticals, Inc., or Alexion, a pharmaceutical company, including vice president, North America commercial and global general and administrative finance from May 2016 to May 2017 vice president, corporate financial planning and analysis from February 2014 to May 2016 executive director, finance from July 2011 to February 2014 and senior director, finance and planning from January 2009 to July 2011. Prior to joining Alexion, Mr. Basso served in various finance roles at Pfizer Inc., or Pfizer, a pharmaceutical company. Mr. Basso received a B.S. in business from Providence College and an M.B.A. from Boston College.
- Henric Bjarke
Henric Bjarke自2017年7月起担任我们的高级副总裁兼首席运营官。在加入我们公司之前，Bjarke先生于2015年9月至2017年4月担任Iveric的高级副总裁，首席商务官。Bjarke先生于2012年11月至2015年8月担任Alexion全球代谢紊乱专营权Vice President，并于2010年9月至2012年11月担任Alexion北美商业运营Vice President。加入Alexion之前，Bjarke在Watson Pharmaceuticals，Eyetech Pharmaceuticals，Inc.和Pharmacia Corporation担任多个商业职位。Bjarke先生在瑞典乌普萨拉大学（Uppsala University）获得工商管理与经济学学士学位。
Henric Bjarke has served as our senior vice president and chief operating officer since July 2017. Prior to joining our company, Mr. Bjarke served as senior vice president, chief commercial officer of IVERIC from September 2015 to April 2017. Mr. Bjarke served as vice president, global metabolic disorders franchise of Alexion from November 2012 to August 2015 and as vice president, North America commercial operations of Alexion from September 2010 to November 2012. Prior to joining Alexion, Mr. Bjarke served in various commercial roles at Watson Pharmaceuticals, Eyetech Pharmaceuticals, Inc. and Pharmacia Corporation. Mr. Bjarke received a B.A. Sc. in business administration and economics from Uppsala University in Sweden.- Henric Bjarke自2017年7月起担任我们的高级副总裁兼首席运营官。在加入我们公司之前，Bjarke先生于2015年9月至2017年4月担任Iveric的高级副总裁，首席商务官。Bjarke先生于2012年11月至2015年8月担任Alexion全球代谢紊乱专营权Vice President，并于2010年9月至2012年11月担任Alexion北美商业运营Vice President。加入Alexion之前，Bjarke在Watson Pharmaceuticals，Eyetech Pharmaceuticals，Inc.和Pharmacia Corporation担任多个商业职位。Bjarke先生在瑞典乌普萨拉大学（Uppsala University）获得工商管理与经济学学士学位。
- Henric Bjarke has served as our senior vice president and chief operating officer since July 2017. Prior to joining our company, Mr. Bjarke served as senior vice president, chief commercial officer of IVERIC from September 2015 to April 2017. Mr. Bjarke served as vice president, global metabolic disorders franchise of Alexion from November 2012 to August 2015 and as vice president, North America commercial operations of Alexion from September 2010 to November 2012. Prior to joining Alexion, Mr. Bjarke served in various commercial roles at Watson Pharmaceuticals, Eyetech Pharmaceuticals, Inc. and Pharmacia Corporation. Mr. Bjarke received a B.A. Sc. in business administration and economics from Uppsala University in Sweden.
- Steven Jungles
Steven Jungles自2017年5月起担任我们的高级副总裁兼首席技术运营官。Jungles先生还自2015年4月起担任生物制药咨询公司SJJ BioConsulting LLC的顾问。Jungles先生于2011年7月至2015年4月担任制药公司Ultragenyx PharmaceuticalInc.技术运营高级副总裁，并于1999年至2011年7月在制药公司BioMarin Pharmaceutical，Inc.担任多个职位。Jungles先生在爱荷华大学（University of Iowa）获得生物学学士学位。
Steven Jungles has served as our senior vice president and chief technical operations officer since May 2017. Mr. Jungles has also served as a consultant to SJJ BioConsulting LLC, a biopharmaceutical consulting company, since April 2015. Mr. Jungles served as senior vice president of technical operations at Ultragenyx Pharmaceutical Inc., a pharmaceutical company, from July 2011 to April 2015 and in various roles at BioMarin Pharmaceutical, Inc., a pharmaceutical company, from 1999 to July 2011. Mr. Jungles received a B.S. in biology from the University of Iowa.- Steven Jungles自2017年5月起担任我们的高级副总裁兼首席技术运营官。Jungles先生还自2015年4月起担任生物制药咨询公司SJJ BioConsulting LLC的顾问。Jungles先生于2011年7月至2015年4月担任制药公司Ultragenyx PharmaceuticalInc.技术运营高级副总裁，并于1999年至2011年7月在制药公司BioMarin Pharmaceutical，Inc.担任多个职位。Jungles先生在爱荷华大学（University of Iowa）获得生物学学士学位。
- Steven Jungles has served as our senior vice president and chief technical operations officer since May 2017. Mr. Jungles has also served as a consultant to SJJ BioConsulting LLC, a biopharmaceutical consulting company, since April 2015. Mr. Jungles served as senior vice president of technical operations at Ultragenyx Pharmaceutical Inc., a pharmaceutical company, from July 2011 to April 2015 and in various roles at BioMarin Pharmaceutical, Inc., a pharmaceutical company, from 1999 to July 2011. Mr. Jungles received a B.S. in biology from the University of Iowa.
- Axel Bolte
Axel Bolte，2003年12月起，担任本公司董事。2003年3月起，他担任HBM Partners AG的投资顾问，这是生命科学行业的投资咨询服务提供商。2001年3月至2003年2月，他是NMT New Medical Technologies AG的投资经理，这是专注于生命科学行业的瑞士风投公司。加入NMT New Medical Technologies AG之前，他是生物技术公司Serono SA的科学家。他目前担任一些生物技术公司的董事，其中包括：Newron Pharmaceuticals SpA、Nabriva Therapeutics AG、Opthotech Corporation、MPex Pharmaceuticals, Inc.、Lux Biosciences, Inc.和 Kolltan Pharmaceuticals, Inc.。他获得了瑞士University of St. Gallen的工商管理硕士学士学位、瑞士苏黎世Swiss Federal Institute of Technology的生物化学学位。
Axel Bolte has served as a member of our board of directors since August 2007. From March 2003 through January 2017 Mr. Bolte served as investment advisor to HBM Partners AG, a provider of investment advisory services in the life sciences industry. From February 2017 to September 2019 Mr. Bolte served as a venture partner to HBM Partners AG. In February 2017 Mr. Bolte began serving as president and chief executive officer of Inozyme Pharma Inc., a private biotechnology company, and as a managing member of Healthcare Advisors GmbH, a private healthcare advisory company. Mr. Bolte previously served on the boards of directors of Allena Pharmaceuticals, Inc. and Nabriva Therapeutics AG, both of which are publicly traded biotechnology or pharmaceutical companies. Mr. Bolte received a degree in biochemistry from the Swiss Federal Institute of Technology, Zurich, Switzerland and an M.B.A. from the University of St. Gallen, Switzerland.- Axel Bolte，2003年12月起，担任本公司董事。2003年3月起，他担任HBM Partners AG的投资顾问，这是生命科学行业的投资咨询服务提供商。2001年3月至2003年2月，他是NMT New Medical Technologies AG的投资经理，这是专注于生命科学行业的瑞士风投公司。加入NMT New Medical Technologies AG之前，他是生物技术公司Serono SA的科学家。他目前担任一些生物技术公司的董事，其中包括：Newron Pharmaceuticals SpA、Nabriva Therapeutics AG、Opthotech Corporation、MPex Pharmaceuticals, Inc.、Lux Biosciences, Inc.和 Kolltan Pharmaceuticals, Inc.。他获得了瑞士University of St. Gallen的工商管理硕士学士学位、瑞士苏黎世Swiss Federal Institute of Technology的生物化学学位。
- Axel Bolte has served as a member of our board of directors since August 2007. From March 2003 through January 2017 Mr. Bolte served as investment advisor to HBM Partners AG, a provider of investment advisory services in the life sciences industry. From February 2017 to September 2019 Mr. Bolte served as a venture partner to HBM Partners AG. In February 2017 Mr. Bolte began serving as president and chief executive officer of Inozyme Pharma Inc., a private biotechnology company, and as a managing member of Healthcare Advisors GmbH, a private healthcare advisory company. Mr. Bolte previously served on the boards of directors of Allena Pharmaceuticals, Inc. and Nabriva Therapeutics AG, both of which are publicly traded biotechnology or pharmaceutical companies. Mr. Bolte received a degree in biochemistry from the Swiss Federal Institute of Technology, Zurich, Switzerland and an M.B.A. from the University of St. Gallen, Switzerland.